Not provided
Not provided
Not provided
Not provided
Major delays attributed to COVID-19 pandemic. Learnings informed design of multi-centre RCT
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Open, Single arm intervention, feasibility study
The aims of the proposed feasibility study are to assess whether a low-energy meal replacement plan (MRP) in patients with HFpEF and T2D:
1. Is acceptable to an older, co-morbid, multi-ethnic population
The secondary objectives are to assess whether a low-energy MRP in patients with HFpEF and T2D may be:
All patients will undergo the following assessments at baseline, 12-weeks and 12 months (following MRP):
12. At the end of the 12-week intervention, participants will be invited to a semi-structured interview to explore qualitative aspects of the study to guide future trial design.
13. At 12 months attendance at cardiac rehabilitation will be reviewed.
The MRP provided by Cambridge Weight Plan® contains ~810 kcal/day (30% protein, 50% carbohydrate, 20% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Low energy meal replacement plan 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low energy meal replacement plan (12 weeks) | Dietary Supplement | Low energy meal replacement plan (12 weeks) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment and retention rates | The number of people approached, recruited and retained | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in 6 minute walk test pre- and post intervention | Meters walked within 6 minutes | 12 weeks |
| Differences in cardiopulmonary exercise test (peak VO2) pre- and post intervention | exercise test on a static bike using minute by minute ventilatory gas analysis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardiovascular Research Centre (Glenfield Hospital) | Leicester | Leicestershire | LE3 9QP | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Low energy meal replacement plan for 12 weeks
Not provided
Not provided
Not provided
Not provided
| 12 weeks |
| Differences in LV remodelling (indexed LV mass) pre- and post intervention | CMR measures of cardiac geometry | 12 weeks |
| Differences in LV function pre- and post intervention | CMR measures of cardiac function | 12 weeks |
| Differences in E/A ratio pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in E (cm/s) pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in MV deceleration time (ms) pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in A (cm/s) pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in Septal e' pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in Lateral e' pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in Septal E/e' pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in Lateral E/e' pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in Average E/e' pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in LA volume indexed pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in TR jet velocity (m/s) pre- and post intervention | Standard clinical echocardiography | 12 weeks |
| Differences in BMI pre- and post intervention | Weighing scales and stadiometer measurement (Kg/m2) | 12 weeks |
| Differences in Bone Mineral Density (g/cm2) pre- and post intervention | DEXA scan | 12 weeks |
| Differences in Total Fat mass (g) pre- and post intervention | DEXA scan | 12 weeks |
| Differences in Total tissue fat (%) pre- and post intervention | DEXA scan | 12 weeks |
| Differences in visceral adipose tissue mass (g) pre- and post intervention | DEXA scan | 12 weeks |
| Differences in visceral adipose tissue volume (cm3) pre- and post intervention | DEXA scan | 12 weeks |
| Differences in Total lean body mass (g) pre- and post intervention | DEXA scan | 12 weeks |
| Difference in World Health Organisation Disability Schedule (WHODAS 2.0) pre- and post intervention | Scale 0 - 48 with lower scores indicating better outcome | 12 weeks |
| Difference in Medical Research Council Dyspnoea Scale pre- and post intervention | scale 1 - 5 with lower scores indicating better outcome | 12 weeks |
| Difference in Minnesota Living with heart Failure Questionnaire pre- and post intervention | Scale 0 - 105 with lower scores indicating better outcome | 12 weeks |
| Differences in Fasting Glucose (mmol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in HbA1c (%) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in HbA1c (mmol/mol) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in B-type (ng/L) natriuretic peptide pre- and post intervention | Biochemistry | 12 weeks |
| Differences in hs-troponin (ng/L) natriuretic peptide pre- and post intervention | Biochemistry | 12 weeks |
| Differences in CRP (mg/L), natriuretic peptide pre- and post intervention | Biochemistry | 12 weeks |
| Differences in albumin concentration pre- and post intervention | Biochemistry | 12 weeks |
| Differences in albumin/creatinine ratio concentration pre- and post intervention | Biochemistry | 12 weeks |
| Differences in sodium (mmol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in potassium (mmol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in Urea (mmol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in creatinine (umol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in eGFR (ml/min) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in hsTnl(ng/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in hALT (iu/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in ALP (iu/L)pre- and post intervention | Biochemistry | 12 weeks |
| Differences in LDL (mmol/L) pre- and post intervention | Biochemistry | 12 weeks |
| Differences in kidney function pre- and post intervention | Blood analysis for eGFR (ml/min) | 12 weeks |
| Differences in liver function pre- and post intervention | Blood analysis for ALP (iu/L) | 12 weeks |
| Differences in the levels of physical activity pre- and post intervention | Objectively measured with an accelerometer | 12 weeks |
| Cardiac rehabilitation uptake | The proportion of participants who were offered and attended cardiac rehabilitation following completion of the intervention (%) | 12 months |
| The number of participants who experience any Major Adverse Cardiovascular Events (MACE) | At any point during the study if a participant experiences a major cardiovascular event this will be recorded and reported to sponsor in line with handling serious adverse events | 12 weeks |